2762 related articles for article (PubMed ID: 27225694)
21. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
[No Abstract] [Full Text] [Related]
22. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
[No Abstract] [Full Text] [Related]
24. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
25. Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Izumi M; Ogawa K; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Koh Y; Kawaguchi T
Cancer Sci; 2019 Oct; 110(10):3244-3254. PubMed ID: 31368625
[TBL] [Abstract][Full Text] [Related]
26. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
27. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
28. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
[TBL] [Abstract][Full Text] [Related]
30. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
Wang CC; Huang KT; Chang HC; Tseng CC; Lai CH; Lan J; Liu TT; Huang CC; Lin MC
Thorac Cancer; 2022 Jan; 13(1):38-47. PubMed ID: 34841687
[TBL] [Abstract][Full Text] [Related]
33. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
[TBL] [Abstract][Full Text] [Related]
34. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
35. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.
Lin K; Cheng J; Yang T; Li Y; Zhu B
Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):95-101. PubMed ID: 25998384
[TBL] [Abstract][Full Text] [Related]
36. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
[TBL] [Abstract][Full Text] [Related]
37. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
38. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Takashima Y; Sakakibara-Konishi J; Hatanaka Y; Hatanaka KC; Ohhara Y; Oizumi S; Hida Y; Kaga K; Kinoshita I; Dosaka-Akita H; Matsuno Y; Nishimura M
Clin Lung Cancer; 2018 Jul; 19(4):352-359.e1. PubMed ID: 29544718
[TBL] [Abstract][Full Text] [Related]
40. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
